Ensituximab

N/A

Report date: 2024/12/16 14:39:23

Base Information

Drug NameEnsituximab
Drug Alias NameNEO-102NPC-1-CNEO-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsMucin-5AC inhibitors
TargetsMucin-5AC
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeogenix Oncology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPrecision Biologics Inc
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksKEGG